ZEB1 as an indicator of tumor recurrence for areca quid chewing‐associated oral squamous cell carcinomas

E-ISSN： 1600-0714|904-2512|9|693-698

ISSN： 0904-2512

Source： JOURNAL OF ORAL PATHOLOGY & MEDICINE, Vol.904-2512, Iss.9, 2015-10, pp. : 693-698

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BackgroundOral squamous cell carcinoma (OSCC) is the sixth most prevalent malignancy worldwide and the third most common cancer in developing nation. Most OSCC patients relapse within months after receiving treatment. Therefore, searching the biomarkers of recurrence is urgently required to improve OSCC patient survival.MethodsWe set out to explore whether expression of ZEB1 could be triggered in oral epithelial cells (SG and FaDu) by arecoline in vitro. Control and ZEB1‐knockdown arecoline‐stimulated SG and FaDu were subjected to migration/invasiveness/anchorage‐independent growth assay. Primary and recurrent OSCC tissues from areca quid chewers were analyzed using real‐time RT‐PCR analysis for ZEB1 expression.ResultsArecoline led to dose‐dependent elevation of ZEB1 expression in SG and FaDu cells. Downregulation of ZEB1 by lentiviral infection significantly reversed arecoline‐induced oncogenicity including migration ability, cell invasiveness, and anchorage‐independent growth in SG and FaDu cells. Clinically, the level of ZEB1 expression was higher in recurrent OSCC tumor samples but lower in primary lesions.ConclusionsTargeting ZEB1 might offer a new strategy for the treatment of OSCC patients. ZEB1 can serve as a progression and relapse marker in OSCC patients.